Solvonis Therapeutics Plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Anthony James Tennyson
- Full Time Employees
- 6
- Sector
- Producer manufacturing
- Industry
- Miscellaneous manufacturing
- Address
- Eccleston Yards London GL United Kingdom SW1W 9NF
- IPO Date
- Jan 6, 2022
- Website
- solvonis.com
- Similar Companies
- Business
- Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company that develops novel small-molecule therapeutics and repurposed compounds for high-burden central nervous system disorders, with a primary focus on addiction, psychiatry and neurology. The company advances a differentiated pipeline targeting neuropsychiatric conditions including Alcohol Use Disorder (AUD), affecting over 40 million people across the US, UK and EU4 markets; Post-Traumatic Stress Disorder (PTSD), impacting more than 13 million adults in the US and 20 million across those regions; and emerging areas such as depression, stimulant use disorders involving methamphetamine and cocaine, and comorbid conditions with significant unmet needs. Core assets comprise SVN-001, a novel combination therapy of intravenous ketamine and proprietary cognitive behavioural therapy in Phase 3 for severe AUD across eight UK NHS Trusts, co-funded by the UK Medical Research Council and National Institute for Health and Care Research with completion expected in late 2026 or early 2027; SVN-002 preparing for Phase 2b trials in the US for moderate-to-severe AUD; SVN-SDN-14, a preclinical serotonin-dopamine modulator for PTSD designed to enhance pro-social behaviour and long-term outcomes with positive preclinical results reported in August 2025; and an AI-enabled discovery platform integrating proprietary CNS compound libraries, predictive modelling and translational tools to identify modulators for depression and stimulant addictions. Solvonis Therapeutics plc maintains headquarters in London, UK, where it was originally incorporated, and conducts operations primarily in the UK and US with preclinical and clinical activities extending to EU markets. In recent developments, the company completed the acquisition of Awakn Life Sciences Corp in August 2025, significantly expanding its R&D pipeline by integrating AWKN-001 as SVN-001 and positioning Solvonis as a leader in addiction and mental health therapeutics; raised gross proceeds of 1.25 million pounds in October 2025 through subscription with institutional and strategic investors to advance clinical programmes, expand CNS drug discovery across its three-pillar strategy and strengthen R&D capabilities; secured a 1.0 million pounds subscription from major shareholders in July 2025 to accelerate AI-supported discovery for major depressive disorder and stimulant use disorders; announced in December 2025 that AI-discovered SVN-015 for methamphetamine and cocaine use disorders was accepted into the US National Institute on Drug Abuse Addiction Treatment Discovery Program for funded preclinical evaluation, potentially leading to NIH clinical funding; and appointed global biopharma leader Paul Carter as Non-Executive Director in October 2025 to support strategic growth.
Company News
Dow closes with strong gains as rate fears take a back seat
Bitcoin price recovery narrows odds on higher 2026 targets, prediction market data shows
Bank of Montreal beats earnings estimates on US banking strength
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Nasdaq rises as Wall Street gets relief from falling yields
Dick's Sporting Goods stock craters on earnings miss
Fiserv cuts 2026 outlook as Q2 earnings, revenue miss estimates
US drug agency to fund further testing of Solvonis addiction candidate - UPDATE
US Research house initiates Solvonis coverage citing differentiated addiction strategy
IXICO guidance unchanged after Huntington's cancellations
Solvonis CEO on progress with potential alcohol use disorder treatment - ICYMI
FTSE 100 Live: London stocks outperform as tech selloff sees SpaceX slide
3M maintains positive outlook for 2026 amid order momentum
Fed hawkishness and stretched valuations offset Iran deal relief, Deutsche Bank says
Solvonis shares up 12% after clears key hurdle in bid to treat alcohol addiction with esketamine treatment - UPDATE
Lindian Resources keeps Kangankunde on track for Q4 first production as mining readiness accelerates
Netflix, Amazon named among UBS top technology, media and telecommunications stocks picks
Whoop valuation tops $10B, setting up highly anticipated IPO
Progress Software raises full-year outlook after delivering strong Q1 results
Valereum, Solvonis Therapeutics, RC Fornax, Active Energy, Plexus, Quantum Helium - Small Cap Snapshot